Circulating levels of microRNA 423-5p are associated with 90 day mortality in cardiogenic shock
Por:
Jantti, T, Segersvard, H, Tolppanen, H, Tarvasmaki, T, Lassus, J, Devaux, Y, Vausort, M, Pulkki, K, Sionis, A, Bayes-Genis, A, Tikkanen, I, Lakkisto, P and Harjola, VP
Publicada:
1 feb 2019
Ahead of Print:
24 nov 2018
Categoría:
Cardiology and cardiovascular medicine
Resumen:
Aims The role of microRNAs has not been studied in cardiogenic shock. We examined the potential role of miR-423-5p level to predict mortality and associations of miR-423-5p with prognostic markers in cardiogenic shock.
Methods and results We conducted a prospective multinational observational study enrolling consecutive cardiogenic shock patients. Blood samples were available for 179 patients at baseline to determine levels of miR-423-5p and other biomarkers. Patients were treated according to local practice. Main outcome was 90 day all-cause mortality. Median miR-423-5p level was significantly higher in 90 day non-survivors [median 0.008 arbitrary units (AU) (interquartile range 0.003-0.017) vs. 0.004 AU (0.002-0.009), P = 0.003]. miR-423-5p level above median was associated with higher lactate (median 3.7 vs. 2.4 mmol/L, P = 0.001) and alanine aminotransferase levels (median 68 vs. 35 IU/L, P < 0.001) as well as lower cardiac index (1.8 vs. 2.4, P = 0.04) and estimated glomerular filtration rate (56 vs. 70 mL/min/1.73 m(2), P = 0.002). In Cox regression analysis, miR-423-5p level above median was associated with 90 day all-cause mortality independently of established risk factors of cardiogenic shock [adjusted hazard ratio 1.9 (95% confidence interval 1.2-3.2), P = 0.01].
Conclusions In cardiogenic shock patients, above median level of miR-423-5p at baseline is associated with markers of hypoperfusion and seems to independently predict 90 day all-cause mortality.
Filiaciones:
Jantti, T:
Univ Helsinki, Dept Internal Med, Helsinki, Finland
Helsinki Univ Hosp, Helsinki, Finland
Segersvard, H:
Minerva Fdn, Helsinki, Finland
Univ Helsinki, Helsinki, Finland
Tolppanen, H:
Univ Helsinki, Dept Cardiol, Helsinki, Finland
Helsinki Univ Hosp, Heart & Lung Ctr, Helsinki, Finland
Tarvasmaki, T:
Univ Helsinki, Dept Cardiol, Helsinki, Finland
Helsinki Univ Hosp, Heart & Lung Ctr, Helsinki, Finland
Lassus, J:
Univ Helsinki, Dept Cardiol, Helsinki, Finland
Helsinki Univ Hosp, Heart & Lung Ctr, Helsinki, Finland
Devaux, Y:
Luxembourg Inst Hlth, Cardiovasc Res Unit, Strassen, Luxembourg
Vausort, M:
Luxembourg Inst Hlth, Cardiovasc Res Unit, Strassen, Luxembourg
Pulkki, K:
Univ Eastern Finland, Dept Clin Chem, Kuopio, Finland
Eastern Finland Lab Ctr ISLAB, Kuopio, Finland
Sionis, A:
Univ Autonoma Barcelona, Biomed Res Inst IIB St Pau, Hosp Santa Creu & St Pau, Intens Cardiac Care Unit,Cardiol Dept, Barcelona, Spain
:
Hosp Badalona Germans Trias & Pujol, Heart Inst, Badalona, Spain
Autonomous Univ Barcelona, Dept Med, CIBERCV, Barcelona, Spain
Tikkanen, I:
Minerva Fdn, Helsinki, Finland
Univ Helsinki, Helsinki, Finland
Univ Helsinki, Div Nephrol, Helsinki, Finland
Helsinki Univ Hosp, Abdominal Ctr, Div Nephrol, Helsinki, Finland
Lakkisto, P:
Minerva Fdn, Helsinki, Finland
Univ Helsinki, Helsinki, Finland
Univ Helsinki, Dept Clin Chem, Helsinki, Finland
Helsinki Univ Hosp, Dept Clin Chem, Helsinki, Finland
Harjola, VP:
Univ Helsinki, Div Emergency Med, Helsinki, Finland
Helsinki Univ Hosp, Dept Emergency Med & Serv, Helsinki, Finland
gold, Green Published
|